A Study of Galcanezumab in Healthy Participants.

NCT02836613 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: Galcanezumab

Sponsor

Eli Lilly and Company